MktsMarkets

Jazz Pharmaceuticals plc
NASDAQ: JAZZKey statistics
JAZZ News
Stories mentioning JAZZ from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1,068,900 | 1,197,967 | 1,126,107 | 1,045,712 | 897,800 | 1,088,173 | 1,054,969 | 1,023,825 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | ||||||||
| Sales General & Admin | 352,700 | 406,225 | 530,647 | 358,399 | 514,000 | 369,287 | 325,772 | 338,523 |
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | 336,600 | 254,543 | 57,509 | (686,392) | (55,900) | 190,770 | 260,210 | 199,443 |
| Interest Income | 23,400 | 20,500 | 18,600 | 19,100 | 27,600 | 31,600 | 26,000 | 25,400 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | 6,100 | 4,951 | (242,424) | (17,170) | (17,800) | (57,912) | (14,533) | (30,653) |
| Net Income (Loss) | 293,100 | 203,410 | 251,412 | (718,470) | (92,500) | 191,115 | 215,055 | 168,568 |
| Earnings Per Share (Basic) | 4.73 | 3.34 | 4.14 | (11.74) | (1.52) | 3.09 | 3.50 | 2.68 |
| Earnings Per Share (Diluted) | 4.43 | 3.34 | 4.08 | (11.74) | (1.52) | 2.90 | 3.42 | 2.49 |
| Weighted Average Shares Outstanding (Basic) | 61,900 | 60,981 | 60,696 | 61,194 | 61,000 | 61,838 | 61,414 | 62,882 |
| Weighted Average Shares Outstanding (Diluted) | 66,100 | 60,981 | 61,606 | 61,194 | 61,000 | 66,007 | 63,174 | 69,625 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About JAZZ
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a stock listed on the Nasdaq Stock Market under the ticker symbol JAZZ. It last traded at $243.54 (Nov 9, 2026, 4:00 PM ET), up 3.7% on the day. That gives Jazz Pharmaceuticals a market capitalisation of $15.5B and a price-to-earnings ratio of 75.0.
Over the past 52 weeks JAZZ has traded between $128.80 and $266.38.
Revenue for the quarter ended Mar 31, 2026 was $1.1B; net income $293.1M. Revenue was up 19.1% from $897.8M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $1.1B | $293.1M | 27.4% |
| Dec 31, 2025 | $1.2B | $203.4M | 17.0% |
| Sep 30, 2025 | $1.1B | $251.4M | 22.3% |
| Jun 30, 2025 | $1.0B | -$718.5M | -68.7% |
From Jazz Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…